Table 1.
Clinical characteristics of the SG and CG.
| Variables | Chronic statin users N = 33 (%) | Control group N = 33 (%) | p-value |
|---|---|---|---|
| Age (Mean ± S.D.) | 66,5 ± 12,1 | 64,9 ± 11,2 | 0,57 |
| Females/Men | 14/19 (42,4/57,6) | 17/16 (51,5/48,5) | 0,46 |
| Overweight BMI ≥ 25: Yes/No |
5/28 (15,2/84,8) | – | – |
| Statin type: Atorvastatin/Lovastatin/Rosuvastatin/Simvastatin |
6/2/4/21 (18,2/6,1/12,1/63,6) | – | – |
| Indication for the statin use H/HFH/PCE |
28/3/2 (84,8/9,1/6,1) | – | – |
| Hypertension: Yes/No | 9/24 (27,3/72,7) | – | – |
| Severity of other COVID-19 symptoms: fever, rhinitis, headache, cough. | 13/11/3/6 (39,4/33,3/9,1/18,2) | 8/16/8/1 (24,2/48,5/24,2/3,03) | 0,009* |
| CpK level Normal/Elevated/High/Lack of data |
9/9/5/10 (27,3/27,3/15,1/30,3) |
29/4/-/- (87,9/12,1/-/-) |
<0,0001* |
| Muscle symptoms: Muscle pain: Mild/Moderate/Severe Muscle weakness: Yes/ No |
9/8/16 (27,3/24,2/48,5) 20/13 (60,6/39,4) |
16/15/2 (48,5/45,4/6,1) 5/28 (15,2/84,8) |
0,003* 0,0002* |
Abbreviations used: CpK- Creatine kinase; H – Hypercholesterolaemia; HFH - Homozygous familial hypercholesterolaemia; PCE - Prevention of cardiovascular events.